In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance

Diabetes

Volumn 51, Issue 10, 2002, Pages 3102-3106

  Kopprasch, Steffi ^a   Pietzsch, Jens ^b   Kuhlisch, Eberhard ^a   Fuecker, Katja ^a   Temelkova Kurktschiev, Theodora ^c   Hanefeld, Markolf ^c   Kühne, Helmut ^a   Julius, Ulrich ^a   Graessler, Jürgen ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c Center for Clinical Studies   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; IN VIVO STUDY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0036789253     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.10.3102     Document Type: Article

References (31)

1. Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272:20963-20966, 1997
2. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F: Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:844-848, 2001
3. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R: Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103:1955-1960, 2001
4. Laakso M, Kuusisto J: Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Ann Med 28:415-418, 1996
5. The DECODE study group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria: the DECODE study group: European Diabetes Epidemiology Group: diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 354:617-621, 1999
6. Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T: Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RLAD study. Diabet Med 17:835-840, 2000
7. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R: Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20:2243-2247, 2000
8. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D: Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98:1487-1494, 1998
9. Pietzsch J, Julius U, Nitzsche S, Hanefeld M: In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 47:1928-1934, 1998
10. Kopprasch S, Graessler J, Kohl M, Bergmann S, Schröder HE: Comparison of circulating phagocyte oxidative activity measured by chemiluminescence in whole blood and isolated polymorphonuclear leukocytes. Clin Chim Acta 253:145-157, 1996
11. Metsä-Ketelä T: Luminescent assay for total peroxyl radical-trapping capability of plasma. In Bioluminescence and Chemiluminescence: Current Status. Stanley P, Kricka L, Eds. Chichester, NY, John Wiley, 1991, p. 389-392
12. Benzie FF, Chung W, Tomlinson B: Simultaneous measurement of allantoin and urate in plasma: analytical evaluation and potential clinical application in oxidant:antioxidant balance studies. Clin Chem 45:901-904, 1999
13. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C: Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 9:2082-2088, 1998
14. Boizel R, Benhamou PY, Lardy B, Laporte F, Foulon T, Halimi S: Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 23:1679-1685, 2000
15. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1-9, 1999
16. Pietzsch J, Lattke P, Julius U: Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time: in vivo insights from stable-isotope studies. Arterioscler Thromb Vasc Biol 20:E63-E67, 2000
17. Allen RC, Dale DC, Fletcher BT: Blood phagocyte luminescence: gauging systemic immune activation. Methods Enzymol 305:591-629, 2000
18. Fuller CJ, Agil A, Lender D, Jialal I: Superoxide production and LDL oxidation by diabetic neutrophils. J Diabetes Complic 10:206-210, 1996
19. Shurtz-Swirski R, Shapiro G, Sela S, Nasser L, Herskovits AT, Kristal B, Shasha SM: Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care 24:104-110, 2001
20. Frei B, Stocker R, Ames BN: Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci U S A 85:9748-9752, 1988
21. Kopprasch S, Richter K, Leonhardt W, Pietzsch J, Graessler J: Urate attenuates oxidation of native low-density lipoprotein by hypochlorite and the subsequent lipoprotein-induced respiratory burst activities of polymorphonuclear leukocytes. Mol Cell Biochem 206:51-56, 2000
22. Grootveld M, Halliwell B: Measurement of allantoin and uric acid in human body fluids: a potential index of free-radical reactions in vivo? Biochem J 243:803-808, 1987
23. Mackness MI, Durrington PN: HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 115:243-253, 1995
24. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN: Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15:1812-1818, 1995
25. Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, Ito H, Kumon Y, Hashimoto K: Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47:598-602, 1998
26. Haffner SM, Mykkänen L, Robbins D, Valdez R, Miettinen H, Howard BV, Stern MP Bowsher R: A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects. Diabetologia 38:1328-1336, 1995
27. Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A: Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 88:2180-2189, 1993
28. Pietzsch J, Julius U, Kirch C, Fischer S, Hanefeld M: Very low density lipoprotein (VLDL) overproduction is maximally expressed in early insulin resistant states. Ann N Y Acad Sci 892:319-322, 1999
29. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Ahlstrom C, Fager G, Bondjers G: Effect of arterial proteoglycans and glycosaminoglycans on low-density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb 12:569-583, 1992
30. Esterbauer H, Juergens G: Mechanistic and genetic aspects of susceptibility of LDL to oxidation. Curr Opin Lipidol 4:114-124, 1993
31. Pietzsch J, Julius U: Different susceptibility to oxidation of proline and arginine residues of apolipoprotein B-100 among subspecies of low density lipoproteins. FEBS Lett 491:123-126, 2001